Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAG1 | P54619 | 1/20 | 0.45 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.45 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | ALPL | P05186 | 1/20 | 0.40 |
| ▸ | HAO1 | Q9UJM8 | 3/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22795420 | 0.90 | PRKAG1 (0.43) | PRKAG1PRKAA1PRKAB1CA9ALPL | |
| SCHEMBL21296894 | 0.90 | PRKAG1 (0.43) | PRKAG1PRKAA1PRKAB1CA9ALPL | |
| SCHEMBL29799163 | 0.90 | PRKAG1 (0.43) | PRKAG1PRKAA1PRKAB1CA9ALPL | |
| SCHEMBL22795588 | 0.88 | ERN1 (0.46) | PRKAG1PRKAA1PRKAB1ALDH1A1CA9 | |
| SCHEMBL21296847 | 0.87 | PRKAG1 (0.51) | PRKAG1PRKAA1PRKAB1MAPTGAA | |
| SCHEMBL21296952 | 0.85 | RXRA (0.51) | PRKAG1PRKAA1PRKAB1MAPTALDH1A1 | |
| SCHEMBL21296929 | 0.84 | PIN1 (0.49) | PRKAG1PRKAA1PRKAB1MAPTPTGER4 | |
| SCHEMBL21296956 | 0.83 | HAO1 (0.52) | PRKAG1PRKAA1PRKAB1CA9ALPL | |
| SCHEMBL21296954 | 0.82 | PRKAG1 (0.50) | PRKAG1PRKAA1PRKAB1MAPTMEN1 | |
| SCHEMBL29799086 | 0.82 | PRKAG1 (0.50) | PRKAG1PRKAA1PRKAB1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11389456-B2 | Compounds and methods for treating oxalate-related diseases | OXALURX, INC. (US) | 2022-07-19 | — | — | US | disclosed |
| US-20200390778-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. | 2020-12-17 | — | — | US | disclosed |
| US-20200390778-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. | 2020-12-17 | — | — | US | disclosed |
| WO-2019165159-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. (US) | 2019-08-29 | — | — | WO | disclosed |
| WO-2019165159-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. (US) | 2019-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200390778-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | XDH, PNPO, LOX | PRKAG1 2580/4885PRKAA1 2860/4885PRKAB1 2716/4885 |
| US-11389456-B2 | Compounds and methods for treating oxalate-related diseases | XDH, PNPO, LOX | PRKAG1 2580/4885PRKAA1 2860/4885PRKAB1 2716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.